Analogic Highlights Groundbreaking Quantum Technology at AUA Annual Meeting

Analogic Corporation

17.05.2012 19:45

New BK Medical Ultrasound Systems With Quantum Technology Offer Exceptional Image Quality

PEABODY, Mass., 2012-05-17 19:45 CEST (GLOBE NEWSWIRE) — Analogic Corporation (Nasdaq:ALOG), enabling the world’s medical imaging and aviation security technology, today announced that it will demonstrate its suite of new BK Medical branded ultrasound systems–the Flex Focus(tm) 500, Flex Focus 800, and Pro Focus(tm) UltraView 800 with the groundbreaking Quantum(tm) Technology–at the American Urological Association Annual Meeting, May 19-23, in Atlanta. Analogic’s BK Medical branded systems with Quantum Technology offer new features and solutions that provide clinicians a faster and easier way to maximize ultrasound performance, specifically in urology and renal imaging.

Quantum Technology offers image quality advancements including improved contrast resolution, as well as new grayscale maps and new image pre-sets, making it easier and quicker to obtain the highest quality images. In addition, the new technology includes a unique Vector Flow Imaging (VFI) mode*, allowing angle independent visualization of blood flow, and an advanced color Doppler mode, enabling superb spatial resolution. Key benefits also include advanced harmonic imaging when imaging all patient types, even the extremely difficult-to-image patient.

‘The BK Medical ultrasound solution provides excellent 2D imaging, enabling clinicians to visualize kidney anatomy out to the pyramids and capsule with increased color Doppler resolution out to the renal cortex,’ said Lars Shaw, vice president of global marketing at Analogic. ‘In addition, the vector flow imaging mode allows for angle independent visualization of blood flow out to the accurate arteries, leading to a more thorough patient assessment.’

Analogic’s new ultrasound systems complement BK Medical’s extensive product portfolio. The Flex Focus 800 and UltraView 800 are premium performance, highly efficient new systems that incorporate Quantum Technology. Compatible with all of the BK Medical transducers, the fully featured systems are ideally suited for surgery, including robotic-assisted surgery, high-end urology, and general imaging.

The UltraView 800 system also has contrast imaging capabilities**. The Flex Focus 500 is the mid-range system in the BK Medical product family incorporating Quantum Technology. This portable system is powerful and well suited for a busy practice utilizing ultrasound for urology and general imaging needs. All of the new ultrasound systems have the VFI* as an option.

‘Using the BK Medical ART system for robotic-assisted surgery allows us to tackle more difficult, complex lesions that we would not have considered for a minimally invasive approach in the past,’ said Michael Stifelman, M.D., director, Robotic Surgery, NYU Langone Medical Center, New York City. ‘This technology raises image quality, color Doppler sensitivity, and ease of use to a new level for our robotic-assisted surgery practice.’

See the original post here:
Analogic Highlights Groundbreaking Quantum Technology at AUA Annual Meeting

IRVINE, Calif. & LIEGE, Belgium–(BUSINESS WIRE)–

Regulatory News:

MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to support cancer treatment, today issued its business update for the quarter ended March 31, 2012.

Q1 2012 Highlights

Material Events after the Reporting Period

Yesterday, MDxHealth announced the launch of ConfirmMDx for Prostate Cancer in the United States. The ConfirmMDx for Prostate Cancer test helps urologists distinguish patients who have a true-negative prostate biopsy from those who may have occult cancer. Testing will be performed in MDxHealths state-of-the-art Irvine-based CLIA laboratory for physicians submitting prostate tissue samples directly or via its exclusive co-marketing partner PLUS Diagnostics.

On April 26, 2012, MDxHealth and PLUS Diagnostics entered into a marketing agreement for ConfirmMDx for Prostate Cancer. PLUS Diagnostics, a leading anatomic pathology laboratory, will promote MDxHealths prostate cancer test through its U.S. urology network, complementing the Companys direct sales efforts.

MDxHealth Pharmaco Diagnostic revenues have shown two consecutive quarters of growth. The growth trends are encouraging and momentum in this business segment is strong. Epigenetics, the methods to measure changes in genes beyond those in the DNA sequence, is one of the fastest growing fields in cancer and MDxHealth is striving to be the leader in applying epigenetics in cancer diagnostics. We are investing in the commercialization of our brain and prostate tests while continuing to grow our Pharmaco Diagnostic segment, said Dr. Jan Groen, Chief Executive Officer of MDxHealth. He went on to say: Yesterday, we announced the launch in the U.S. of ConfirmMDx for Prostate Cancer, the first clinical product offered from our state-of-the-art Irvine-based CLIA laboratory. Epigenetic markers and technology included in ConfirmMDx for Prostate Cancer have been tested on approximately 4,128 patients with over 42 published studies. We have now hired our own sales team in the U.S. and together with the recent marketing agreement with PLUS Diagnostics, we believe we are on track for successful roll-out of this important test to the urology community. These accomplishments demonstrate our commitment to execute aggressively the new commercial strategy we outlined in October 2010.

Key non-audited financials, as of 31.03.2012

Amounts as at and for the three months ended

See the original post:
MDxHealth Provides First Quarter 2012 Business Update

Buffalo doctors share stories of Kashmir By ELLEN GOLDBAUM Published: May 14, 2012

A Kashmir native and UB clinical associate professor of urology has launched the Ladi Shah Project, Kashmirs first digital oral history archive.

Khurshid A. Guru, a Buffalo surgeon noted internationally for his advances and teaching in the field of robotic-assisted surgery, has created the project as an initiative of the Guru Charitable Foundation, founded by Guru and his wife, Lubna Guru, a pediatrician. The project has been in development since 2009.

The Ladi Shah Project aims to share the meaningful stories of ordinary Kashmiris as a way of preserving the regions unique linguistic and cultural heritage, says Guru. By recording personal anecdotes, such as an artisan explaining the beauty and meaning behind his craft, a retired teacher noting the perils of unquestioning obedience and a social workers struggle to help establish the first blood bank, the Ladi Shah Project creates vivid snapshots of everyday life in Kashmir as it is and as it was. The stories highlight Kashmirs diversity, as well asthe common experiences that define its history and culture.

Interview podcasts are now accessible to the public on the Ladi Shah Project website,, which will share new stories from the expanding archive each month. The archive currently contains more than 150 interviews and extraordinary personal accounts from a broad section of Kashmiris.

The Guru Charitable Foundation is a nonprofit organization devoted to improving the quality of education and medical care in Kashmir.

Read the original here:
Need-to-know news and views for UB faculty and staff

Visit link:
DGAP-News: Analogic Highlights Groundbreaking Quantum Technology at AUA Annual Meeting

See more here:
Mount Sinai Prostate Cancer Surgeon Performs 4000th Robotic-Assisted Radical Prostatectomy

Regulatory News:

Mauna Kea Technologies (Paris:MKEA) (NYSE Euronext: MKEA, FR0010609263), the leader in the endomicroscopy market, today announced highlights of the Fourth Annual International Conference of Cellvizio Users (ICCU), which took place last month in Rome.

Bertrand Napolon, MD, a specialist in gastroenterology at Jean Mermoz Private Hospital in Lyon, France, and Kenneth J. Chang, MD, Professor and Chief, Division of Gastroenterology and Executive Director of the H.H. Chao Comprehensive Digestive Disease Center at the University of California, Irvine School of Medicine, co-chaired the meeting.

The co-chairs designed the program which included more than 29 abstracts, posters and case studies presented by leaders in endoscopy from 14 countries on the use of Cellvizio as an advanced imaging tool across specialties. Topics included outcomes and best practices associated with using Cellvizio as a tool to help improve the diagnosis, treatment and management of patients with digestive and respiratory diseases, as well as, new areas of clinical investigation, including urology, intensive care and robotic surgery. More than 120 international experts in endoscopy, representing numerous fields in medicine, attended the three-day conference.

“This years ICCU provided a robust educational and information-sharing forum on indications associated to endomicroscopy as well as areas currently under research. The exchange amongst users from different countries facilitated a broad understanding of how Cellvizio helps physicians more accurately characterize disease and take more informed and efficient treatment decisions for patients, Dr. Napoleon said. “Seeing the enthusiasm of our American colleagues and the strong potential behind the technology, we feel that we are entering a new era in endoscopy. This is similar to what we experienced with echoendoscopy over 20 years ago.

Cellvizio, a true multidisciplinary platform, provides live, cellular level-views of internal tissues to help physicians better characterize disease in their patients, so they can recommend appropriate treatments more efficiently.

The fourth edition of the International Conference of Cellvizio Users (ICCU) was held in Rome, Italy, from April 13-15, 2012. The core scientific program was extended to new indications, featuring recent and future advances of Cellvizio in gastroenterology, urology, pulmonology and surgery. During off-site working groups, participants explored key applications for the technology. And for the first time, a one-day CME-accredited workshop allowed new users to acquire training on image interpretation and to become more familiar with Cellvizio handling through live procedures.

“The strong interest and excitement for this years ICCU program underscores the medical communitys growing understanding of the impact that endomicroscopy can have on patient outcomes, said Sacha Loiseau, CEO and Founder of Mauna Kea Technologies. “This conference enlisted the contributions of over one hundred practitioners who were able to exchange their experiences so as to better direct their current practices and research towards new applications. We believe this will have an incredibly positive impact on the field going forward and opens the doors for numerous new areas of clinical investigation within GI and pulmonology and entirely new indications, as well.

About Mauna Kea Technologies

Mauna Kea Technologies is a global medical device company and leader in the endomicroscopy market. Thecompany researches, develops and markets innovative tools to visualize and detect abnormalities in thegastro-intestinal and pulmonary tracts. Its flagship product, Cellvizio, a probe-based Confocal LaserEndomicroscopy (pCLE) system, provides physicians and researchers high-resolution cellular views of tissueinside the body. Large, international, multi-center clinical trials have demonstrated Cellvizios ability to helpphysicians more accurately detect early forms of disease and make treatment decisions immediately.Designed to improve patient outcomes and reduce costs within a hospital, Cellvizio can be used with almostany endoscope. Cellvizio has 510(k) clearance from the U.S. Food and Drug Administration and theEuropean CE-Mark for use in the GI and pulmonary tracts.

Read the original:
Mauna Kea Technologies Announces Highlights of 4th Annual International Conference OF Cellvizio® Users (ICCU)

Editor’s Choice Main Category: Urology / Nephrology Article Date: 10 May 2012 – 11:00 PDT

Current Article Ratings:

Glomerular filtration rate (GRF) is a test used to determine whether the kidneys are functioning properly and is used in the diagnosis of chronic kidney disease (CKD). In addition, GRF is an independent predictor of all-cause and cardiovascular mortality and renal failure. According to clinical guidelines, physicians are advised to report estimated GFR when measuring serum creatinine levels.

The researchers said:

In order to assess if estimated GFR calculated by the CKD-EPI equation predicts risk for adverse outcomes more accurately than the MDRD Study equation in a broad range of populations, Kunihiro Matsushita, M.D., Ph.D., of the Johns Hopkins University, Baltimore, and colleagues conducted a meta-analysis using data from 13 CKD cohorts, 25 general population cohorts, and 7 high-risk cohorts (of vascular disease).

The researchers examined data from 1.1 million individuals aged 18+ from 40 countries or regions of Asia, North America and South America, Europe, Oceania, and the Middle East. Data transfer and analyses were carried out between March 2011 and March 2012.

The primary adverse outcomes the researchers examined were:

Furthermore, the the researchers found that around 0.6% of patients were reclassified to a lower category. Participants who were reclassified to a lower category (0.7%) had a higher risk of mortality and ESRD than patients who were not reclassified even after adjusting for different factors, while those who were reclassified to a higher category had lower risks.

According to the researchers, the prevalence of CKD stages 3 to 5 (<60 mL/min/1.73 m2) was lower by the CKD-EPI equation (6.3%) than by the MDRD Study equation (8.7%), as well as in the high-risk cohorts (14.6% vs.17.7%, respectively).

The researchers explained:

Read more from the original source:
Predicting Risk Of Death In End-Stage Kidney Disease, New Equation More Accurate

Public release date: 10-May-2012 [ | E-mail | Share ]

Contact: Linda Gruner l.gruner@elsevier.com 212-633-3923 Elsevier

New York, May 10, 2012 The Journal of Urology , the official journal of the American Urological Association (AUA), has won the 2012 ASAE Gold Circle Award (Peer-Reviewed Journal category).

Michael Sheppard, CPA, CAE, Executive Director, AUA comments, “Earlier this year, the AUA nominated The Journal of Urology for an ASAE Gold Circle Award (Peer-Reviewed Journal category). The Gold Circle Awards are presented annually by the American Society of Association Executives (ASAE) the largest, and the only international organization serving the association community, representing more than 21,000 association executives and industry partners across 10,000 organizations. The Gold Circle Awards honor extraordinary communication efforts across nine categories. The Peer-Reviewed Journal category judged nominees on clarity, completeness of author guidelines, writing style/quality and peer-review process.”

“We commend the AUA and The Journal’s Editors, Editorial Board, and Publications Team led by Mrs. Deborah Polly on this well-deserved award,” comments Glen P. Campbell, Executive Vice President, STM (Scientific, Technical, and Medical) Journals at Elsevier, Publisher of The Journal of Urology. “It recognizes The Journal for accomplishing two critical goals: publishing outstanding research in the specialty of urology while at the same time meeting the clinical and information needs of all AUA members.”

###

About The Journal of Urology

Established in 1917, The Journal of Urology is the official journal of the American Urological Association. It is the most widely read and highly cited journal in the field. It brings to its readership all the clinically relevant information needed to stay at the forefront of this dynamic field. This top-ranking journal presents investigative studies on critical areas of research and practice, survey articles providing short condensations of the best and most important urology literature worldwide and practice-oriented reports on interesting clinical observations. The Journal of Urology is among the Special Library Association (SLA)’s Top 100 Journals in Biology and Medicine, the 100 Most Influential Journals in Biology & Medicine over the last 100 Years as voted by the BioMedical & Life Sciences Division of the Special Libraries Association.

About the American Urological Association

Founded in 1902 and headquartered near Baltimore, Maryland, the American Urological Association is the pre-eminent professional organization for urologists, with more than 15,000 members throughout the world. An educational nonprofit organization, the AUA pursues its mission of fostering the highest standards of urologic care by carrying out a wide variety of programs for members and their patients, including UrologyHealth.org, an award-winning on-line patient education resource, and the American Urological Association Foundation, Inc.

View original post here:
The Journal of Urology® wins 2012 ASAE Gold Circle Award

SEATTLE–(BUSINESS WIRE)–

May 7, 2012–Dendreon Corporation (Nasdaq:DNDN – News) today reported results for the quarter ended March 31, 2012. Net product revenue for the quarter was $82.0 million compared to $27.0 million for the quarter ended March 31, 2011.

Net loss in the first quarter of 2012 was $103.9 million or $0.70 per share, compared to a net loss of $112.8 million, or $0.78 per share, for the same period in 2011. The current period results include approximately $17 million in cash and non-cash severance expenses. Excluding these expenses, the company had a net loss of $87.1 million or $0.59 per share.

As of March 31, 2012, Dendreon had approximately $559.1 million in cash, cash equivalents, and short-term and long-term investments compared to $617.7 million as of December 31, 2011.

Recent Highlights:

Dendreon continues to make significant progress in establishing PROVENGE as the foundation of care for men with advanced prostate cancer, said John H. Johnson, president and chief executive officer. We are pleased to have exceeded our guidance of low single digit quarter-over-quarter growth and the progress we have made in strengthening our commercial organization.

Conference Call Information

Dendreon will host a conference call on Monday, May 7, 2012 at 4:30 p.m. ET. To access the live call, dial 1-877-548-9590 (domestic) or +1-720-545-0037 (international); the conference ID number is 70198839. The call will also be audio webcast and will be available from the Company’s website at http://www.dendreon.com under the “Investor/Webcasts and Presentations” section. A recorded rebroadcast will be available for interested parties unable to participate in the live conference call by dialing 1-800-585-8367 or +1-404-537-3406 for international callers; the conference ID number is 70198839. The replay will be available from 7:30 p.m. EDT on Monday, May 7, until 11:59 p.m. EDT on Monday, May 14. In addition, the webcast will be archived for on-demand listening for 90 days at www.dendreon.com.

About Dendreon

Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development, commercialization and manufacturing of novel therapeutics. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy (ACI) product candidates designed to stimulate an immune response in a variety of tumor types. Dendreon’s first product, PROVENGE (sipuleucel-T), was approved by the U.S. Food and Drug Administration (FDA) in April 2010. Dendreon is exploring the application of additional ACI product candidates and small molecules for the potential treatment of a variety of cancers. The Company is headquartered in Seattle, Washington and is traded on the NASDAQ Global Market under the symbol DNDN. For more information about the Company and its programs, visit http://www.dendreon.com/.

Read the original post:
Dendreon Reports Net PROVENGE Product Revenues of $82 Million, Achieved 6.5% Quarter-Over-Quarter Growth

by Gregory Zeller Published: May 9, 2012 Tags: Advanced Urology Centers of New York, American Cancer Society, American Clinical Laboratory Association, College of American Pathology, Health Care, North Shore-Long Island Jewish Health System, prostate, prostate screenings, Warren Buffet

$119

A Great Value!

You have clicked on a link to information that is exclusive to LIBN subscribers.

Already a paid subscriber but not registered for online access yet? For instructions on how to get premium web access, click here.

Forgot Password?

Start by choosing how you’d like your news delivered.

– Print and Online –

– Online Only –

Pages: 1 2

Read more from the original source:
Long Island doctor calls prostate study a sham

DUBLIN, April 30, 2012 (GLOBE NEWSWIRE) — Further to media speculation, the Board of Warner Chilcott plc (WCRX – News) confirmed today that it is conducting a process to explore a broad range of strategic alternatives to enhance shareholder value, which include preliminary discussions with potential offerors.

These discussions are at a preliminary stage and may or may not lead to an offer for the Company.

The Company does not intend to disclose further developments regarding the process unless and until its Board has approved a specific course of action, or it otherwise deems further disclosure is appropriate or required.

The Company

Warner Chilcott is a leading specialty pharmaceutical company currently focused on the women’s healthcare, gastroenterology, dermatology and urology segments of the branded pharmaceuticals market, primarily in North America. We are a fully integrated Company with internal resources dedicated to the development, manufacturing and promotion of our products. WCRX-G

A person interested in 1% or more of any relevant securities in the Company may from the date of this announcement have disclosure obligations under Rule 8.3 of the Irish Takeover Rules.

The directors of the Company accept responsibility for the information contained in this announcement. To the best of the knowledge and belief of the directors (who have taken all reasonable care to ensure that such is the case) the information contained in this announcement is in accordance with the facts and does not omit anything likely to affect the import of such information.

Goldman Sachs International, which is authorised and regulated in the United Kingdom by the Financial Services Authority, is acting exclusively for the Company and for no-one else in connection with the matters set out in this announcement and will not be responsible to any person other than the Company for providing the protections afforded to clients of Goldman Sachs International, nor for providing advice in relation to the matters set out in this announcement.

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION (DIRECTLY OR INDIRECTLY) IN WHOLE OR IN PART, IN OR INTO CANADA, AUSTRALIA, JAPAN OR ANY OTHER JURISDICTION WHERE THIS WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION.

Go here to see the original:
Review of Strategic Alternatives

Newswise PHILADELPHIA To improve the quality of life in gay men and minorities treated for prostate cancer, a greater awareness of ethnic and sexual preference-related factors is needed to help men choose a more-suitable treatment plan, researchers from Thomas Jefferson University Hospital conclude in a literature review published May 1 in Nature Reviews Urology.

Some of the factors to consider, for example, include increased risk of urinary and bowel function decline in African Americans regardless of treatment received and differing sexual expectations and social support in gay men.

Different communities of men view the effects of prostate cancer treatments very differently, said co-author Edouard J. Trabulsi, M.D., of the Department of Urology and Kimmel Cancer Center at Thomas Jefferson University Hospital, noting the poorer quality of life among certain subpopulations.

Its in the patients best interest for caregivers to acknowledge perceptions and expectations during the treatment decision process, he said. They should take specific demographics, socioeconomic status, and sexual preference into consideration, and tailor an approach based on a patients specific concerns about the implications of various treatments.

Today, many of these confounding factors are poorly documented and poorly addressed by medical practitioners when discussing treatment, be it radical prostatectomy, radiation or androgen deprivation therapy. There is also scant research about prostate-cancer-related quality of life effects in men who have sex with men (MSM).

In this literature review, the authors use several studies to illustrate differences in treatment outcomes, sexual function and coping mechanisms among subpopulations, including African Americans, Latin Americans, Asians and MSM.

According to the analysis, African Americans, who have higher prostate cancer incidence and mortality rates than whites, are less likely to initiate and complete treatment and less likely to trust a physician. They are also at an increased risk of urinary, bowel and general physical function decline, regardless of treatment.

Treatment preferences and sexual outcomes also differ. According to the review, in a study of 665 military men who had the same access to care, white men were three times more likely to choose a radical prostatectomy as their treatment options for low and intermediate risk prostate cancer, whereas African Americans tended to prefer non-surgical treatments, such as external beam radiation therapy.

A multicenter longitudinal cohort study set up to monitor urinary and sexual function in over 1,200 men who underwent radical prostatectomy for clinically localized prostate cancer showed that African Americans were more likely to retain sexual function.

As with African Americans, Latin American men who underwent radiation therapy or a radical prostatectomy demonstrated greater levels of severe sleep dysfunction than whites. They were also are less likely to enter hospice.

Read the original:
Poorer Quality of Life for Gay Men and Minorities After Prostate Cancer Treatment: What Are We Missing?

BUFORD, Ga.–(BUSINESS WIRE)–

Theragenics Corporation (NYSE: TGX – News) expects to release first quarter 2012 financial results before the market opens on May 10, 2012. Following this release, the Company will host a conference call at 11:00 a.m. Eastern.

To participate in the call, dial 877-407-4019 or 201-689-8337. The call is also being webcast and can be accessed via Theragenics website, www.theragenics.com. A replay will be available on the website for one month. A phone replay will be available until Midnight, May 17, 2012 by dialing 877-660-6853 or 201-612-7415, and entering the account # 372 and conference ID 393250.

Theragenics Corporation (NYSE: TGX – News) operates two business segments: its surgical products business and its brachytherapy seed business. Its surgical products business (www.cpmedical.com, www.galtmedical.com, www.needletech.com) manufactures and distributes wound closure, vascular access, and specialty needle products. Wound closure products include sutures, needles and other surgical products. Vascular access includes introducers, guidewires and related products. Specialty needles include coaxial, biopsy, spinal and disposable veress needles, access trocars, and other needle based products. The surgical products segment serves a number of markets and applications, including, among others, interventional cardiology, interventional radiology, vascular surgery, orthopedics, plastic surgery, dental surgery, urology, veterinary medicine, pain management, endoscopy, and spinal surgery. Theragenics brachytherapy business manufactures, markets and distributes seeds used primarily in the minimally invasive treatment of localized prostate cancer. The Companys brachytherapy product line includes its palladium-103 TheraSeed device (www.theraseed.com) and its iodine-125 devices.

Visit link:
Theragenics to Report First Quarter 2012 Financial Results Thursday, May 10

MURRAY HILL, N.J.–(BUSINESS WIRE)–

C. R. Bard, Inc. (BCR – News) today reported 2012 first quarter financial results. First quarter 2012 net sales were $730.0 million, an increase of 4percent over the prior-year period on a reported basis. Excluding the impact of foreign exchange, first quarter 2012 net sales increased 5 percent over the prior-year period.

For the first quarter 2012, net sales in the U.S. were $496.2 million, an increase of 2 percent over the prior-year period. Net sales outside the U.S. were $233.8 million, an increase of 10 percent over the prior-year period on a reported basis. Excluding the impact of foreign exchange, first quarter 2012 net sales outside the U.S. increased 11 percent over the prior-year period.

For the first quarter 2012, net income was $138.7 million and diluted earnings per share available to common shareholders were $1.60, an increase of 5 percent and 7 percent, respectively, as compared to first quarter 2011 results. Adjusting for items that affect comparability between periods as detailed in the tables below, first quarter 2012 net income was $139.5 million and diluted earnings per share available to common shareholders were $1.61, an increase of 4 percent and 7 percent, respectively, as compared to first quarter 2011 results.

Timothy M. Ring, chairman and chief executive officer, commented, The results this quarter reflect a good start to the year. While we havent seen much change in the U.S. environment, our increased focus and investments in international markets have provided rapid returns and strengthened our growth profile. We remain focused on daily execution of our product leadership strategy to take advantage of current opportunities while positioning ourselves for stronger growth in the future.

C. R. Bard, Inc. (www.crbard.com), headquartered in Murray Hill, NJ, is a leading multinational developer, manufacturer and marketer of innovative, life-enhancing medical technologies in the fields of vascular, urology, oncology and surgical specialty products.

This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on managements current expectations, the accuracy of which is necessarily subject to risks and uncertainties. These statements are not historical in nature and use words such as anticipate, estimate, expect, project, intend, forecast, plan, believe, and other words of similar meaning in connection with any discussion of future operating or financial performance. Many factors may cause actual results to differ materially from anticipated results including product developments, sales efforts, income tax matters, the outcomes of contingencies such as legal proceedings, and other economic, business, competitive and regulatory factors. The company undertakes no obligation to update its forward-looking statements. Please refer to the Cautionary Statement Regarding Forward-Looking Information in our December 31, 2011 Form 10-K for more detailed information about these and other factors that may cause actual results to differ materially from those expressed or implied.

2012

2011

Items that affect comparability of results between periods:

See more here:
Bard Announces First Quarter Results

24 April 2012

Plethora Solutions Holdings PLC

(“Plethora” or the “Company”)

Change of Registered Office

The Company announces that, with immediate effect, its registered address has changed to: 1st Floor, St Andrew’s House, 18-20 St Andrew Street, London, EC4A 3AG

All telephone and fax numbers remain the same.

-Ends-

Enquiries:

Plethora Solutions (LSE: PLE.L – news)

Ronald Openshaw, CEO

See the rest here:
Plethora Solutions – Change of Registered Office

Editor’s Choice Academic Journal Main Category: Prostate / Prostate Cancer Also Included In: Urology / Nephrology;Genetics Article Date: 23 Apr 2012 – 13:00 PDT

email to a friend printer friendly opinions

Current Article Ratings:

3 (1 votes)

3 (1 votes)

Men with the mutated BRCA1 gene are also more susceptible to the very aggressive form of prostate cancer. The authors explained that hopefully, their findings may have an impact on the potential screening and treatment procedures for patients with prostate cancer.

If patients who have the mutated BRCA1 gene were detected early, doctors would then be able to monitor them for prostate cancer from a younger age, which would result in prompter and more targeted treatment if the malignancy developed.

In Great Britain, more than 50% of prostate cancer cases are diagnosed in males over the age of 70 years, making age the main risk factor. In this study, however, out of 913 men who underwent screening, three-quarters of the ones carrying the mutated BRCA1 gene had a prostate cancer diagnosis before reaching 64 years of age, indicating clearly that the presence of the faulty gene might serve as an early warning for individuals with a higher risk of developing the disease at a younger age.

Prostate cancer kills 10,000 men every year in the UK; 37,000 new diagnoses are made annually. Prostate cancer, the most common male cancer worldwide, is more common in the United Kingdom than lung cancer. The authors explained that low awareness contributes to the current number of deaths in the country.

Previous studies have shown that 70% of adult males do not know anything about prostate cancer and what its signs and symptoms are. Better awareness could save thousands of lives annually, they added.

See more here:
Males With Mutated BRCA1 Breast Cancer Gene Have Higher Prostate Cancer Risk